LOADING

Advancing regenerative
medicine Targeting Myocardial Infarction
& Heart Failure

HIGHLIGHTS

1 / 5

Pig Studies confirm that FSTL1 treatment results in 50% scar reduction and up to 75% recovery of heart function after myocardial infarction

HIGHLIGHTS

2 / 5

Awarded US patent covering pharmaceutical compositions of FSTL1

HIGHLIGHTS

3 / 5

Awarded NIH SBIR Grant $4.2 M (R&D Diabetic population)

HIGHLIGHTS

4 / 5

Executed collaborative agreement with Phosphorex to develop Q-Beads, a formulation of FSTL1 for subcutaneous delivery

HIGHLIGHTS

5 / 5

Regencor appoints Nodes as exclusive advisors

Our Vision

Myocardial Regeneration
The ultimate goal of clinical cardiology

Regencor's team envisions a future where myocardial infarctions no longer impose incurable & life threatening tissue damage or progression to heart failure

Regencor's Technology

Q-Beads: A true game-changer in heart disease therapy

Our recombinant protein, delivered subcutaneously, reverses the formation of scar tissue. Scar tissue is the most serious complication after a myocardial infarction as it weakens the heart and leads to progressive heart failure.

Learn more about OUR TECHNOLOGY

LEADERSHIP

Thomas Okarma - Chairman, President & CEO of Regencor

Thomas Okarma, MD, PhD
‍Chairman, President & CEO

Pilar Ruiz-Lozano - Chief Scientific Officer at Regencor

Pilar Ruiz-Lozano, PhD
‍Chief Scientific Officer

Mark Mercola - Director at Regencor

Mark Mercola, PhD
‍Director

Meet the team

News & Awards

The latest news from our company

SEE ALL NEWS

Award

June 25, 2019

Regencor awarded AMGEN Golden Ticket 2019

READ MORE

NATURE.COM

Sep 16, 2015

Epicardial FSTL1 reconstitution regenerates the adult mammalian heart

READ MORE

Our TECHNOLOGY

See how
our technology works